Founded in 2008, American CryoStem seeks a strategic financing of up to $7,000,000. The Company is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of Regenerative and Personalized Medicine. The Company has developed Standard Operating Procedures (SOPs) to op…
Founded in 2008, American CryoStem seeks a strategic financing of up to $7,000,000. The Company is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of Regenerative and Personalized Medicine. The Company has developed Standard Operating Procedures (SOPs) to operate a state-of-art, FDA-registered, clinical laboratory in New Jersey dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs). Leveraging its IRB approved platform technologies with developed products the Company is creating a global footprint , of licensed laboratory affiliates and physicians networks to deliver current and future cellular applications. (currently in Hong Kong and Shenzhen, China, 3 more territories in agreement stage)
The Company maintains a strategic portfolio of 15 patents that form its standardized platform which supports a growing pipeline of stem cell applications and biologic products. The Company’s R&D efforts are currently focused with 4 universities and 3 private collaborations to discover, develop and commercialize ADSC therapies by combining its platform products and clinical grade stem cells with synergistic technologies to create jointly developed applications and intellectual property.
Team (1)
Sectors American Cryostem Corporation serves:
Life Sciences
Business Services
Health Care
Join Axial's Private M&A Platform
American Cryostem Corporation connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
